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Background: Tight junctions (TJs) are mainly composed of claudins, occludin, and tight junction adhesion
molecules (JAM). The invasive and metastatic phenotype of highly invasive cancer cells has been related to
abnormal structure and function of TJs, and with expression of activated matrix metalloproteinases (MMPs). The
relevance of these mechanisms responsible for the invasion and metastasis of ovarian carcinoma is unclear.
Similarly, it is not known if the expression of claudin-6, occludin and MMP2 is related with the clinical properties of
these tumors.
Methods: Expression of claudin-6, occludin, and MMP2 was detected in samples of human ovarian cancer tissues
by immunohistochemistry and correlated with the clinical properties of the tumors.
Results: The positive expression rates of claudin-6 and MMP-2 were higher in ovarian papillary serous carcinomas than
n ovarian serous adenomas (P < 0.05). There were no differences in the expression of occludin (P > 0.05). The expression
of claudin-6 and occludin in ovarian cancer was not correlated with patient age, pathological grade, clinical stage, and
metastasis (P > 0.05). MMP-2 expression was enhanced with increased clinical stage and metastasis (P < 0.05), but was
unrelated to patient age or tumor grade (P > 0.05). There were no apparent correlations between expression of
claudin-6, occludin and MMP-2 in ovarian cancer tissue (P > 0.05).
Conclusions: Our data suggest, for the first time, that the claudin-6 and MMP-2 are up-regulated in ovarian papillary
serous carcinomas, MMP-2 expression was enhanced with increased clinical stage and metastasis. Claudin-6 and
MMP-2 may play a positive role in the invasion and metastasis of ovarian cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1775628454106511.
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Ovarian cancer is one of the most common neoplasms
in women and epithelial tumors account for approxi-
mately 90% of ovarian malignancies [1]. The onset of
ovarian cancer is often asymptomatic and not easily de-
tected, but nevertheless often associated with early me-
tastasis and a poor prognosis [2].
The tight junctions (TJs) are mainly located in the
junctional complex of epithelial and endothelial cells,* Correspondence: quancs11@163.com
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reproduction in any medium, provided the orand comprise three essential membrane proteins: clau-
dins, occludins, and tight junction adhesion molecule
(JAM) [3]. There are 27 members in claudins family,
they have variable tissue-specific expression manners [4].
The aberrant expression of the claudin proteins has been
related to various human carcinomas. Some studies have
reported that down-regulation of the claudin, occludin
and other TJ proteins has been considered one of the
important reasons for the loss of cell adhesion, cell po-
larity, invasion and metastasis of malignant tumors [3],
up-regulation of some TJ proteins has also been associ-
ated with the malignant phenotype. But how increasedtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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less clear. On the one hand, claudins up-regulation is re-
lated to a significant disorganization of the tight junction
strands and increased paracellular permeability [5-9],
which have been related to the invasive and metastatic
phenotype of highly invasive cancer cells [10]. On the
other hand, claudins have been shown to promote tumor
invasion by the activition of MMPs [5,11,12].
MMPs are a zinc ion endopeptidase enzyme family,
and the main enzymes responsible for degradation of
extracellular matrix and cancer invasion and metastasis
[13,14]. Their substrates are type IV collagen and the
laminin layer in the basement membrane [15].
This research was conducted to examine the expres-
sion of claudin-6, occludin and MMP-2 in 36 ovarian
papillary serous carcinomas and 26 ovarian serous aden-
omas specimens, and investigate the relationship be-
tween their expression and clinical properties of the
ovarian tumor patients.
Materials and methods
Patients and tissue specimens
A total of 62 ovarian cancer patients received surgery in
the first hospital of Jilin University between January 2006
and October 2007. A total of 36 ovarian papillary serous
carcinoma specimens from patients ranging in age from
14 to 80 years (mean age 47 years) were included in this
study. Pathological examination confirmed the presence
of tumor metastasis in 13 cases but these were not identi-
fied in 23 cases. The disease stages of all the patients were
classified according to TNM clinical stage (UICC 1997
staging criteria). There were 20 cases of Stage I and II
ovarian cancer, 16 cases of Stage III and Stage IV cancer.
Fourteen of the carcinomas were of pathological grade I,
12 cases grade II, and 10 cases of grade III. None of the
cancer patients had received anticancer therapy preope-
ratively. Twenty-six ovarian serous adenomas served as
experimental controls. The clinicopathological features of
the patients are summarized in Table 1. All specimens
were fixed in 10% neutral formalin at room temperature,
dehydrated, and embedded in paraffin. For the use of
these clinical materials for research purposes, prior
patient’s consent and approval from the Ethics Committee
of Jilin University was obtained.
Immunohistochemistry staining
Four-micrometer-thick tissue sections were cut from the
paraffin-embedded blocks. Deparaffinization was per-
formed using a solution containing xylene, and the sec-
tions were rehydrated with graded ethanol. The slides
were placed in target retrieval solution (citrate buffer,
pH 6.0) and boiled for 5 min in a microwave oven. After
the samples had cooled for 30 min, endogenous perox-
idase activity was inhibited by treatment with 3% H2O2for 30 min. The sections were washed with PBS three
times. After a 30-min protein block with normal goat
serum or normal rabbit serum, the samples were incubated
with the following antibodies overnight at 4°C: anti-
claudin-6 (1:100; Santa Cruz Biotechnologies, Santa Cruz,
CA, USA), anti-occludin (1:100; Santa Cruz Biotech-
nologies, Santa Cruz, CA, USA), anti- MMP-2 (1: 100;
Santa Cruz Biotechnologies, Santa Cruz, CA, USA).
Immunostaining was performed using the streptavidin-
biotin-peroxidase complex. The biotin-conjugated sec-
ondary antibody was incubated for 20 min at room
temperature. The colour reagent diaminobenzidine
(Bios, Beijing, China) was used to visualize the bound
antibody. The sections were counterstained with
Mayer’s haematoxylin. The negative controls were han-
dled in the same way but were incubated in PBS instead of
primary antibody.
Negative controls were processed as above without the
primary antibody or normal IgG. Ovarian cancer tissues
sections with positive claudin-6, occludin and MMP-2 were
stained to serve as pisitive controls. The brown staining of
claudin-6, occludin and MMP-2 on the cell membrane
and/or cytoplasm were as classified as positive staining. Im-
munostaining was observed under light microscopy with
400× magnification, and positive cells, negative cells and
total cells of five different visual fields were numbered in
each specimen. Scoring was performed as follows: negative
(−), <5% positive tumor cells; positive (+), ≥5% positive
tumor cells.Statistical analyses
All statistical analysis were performed using SPSS 12.0
software. Chi-square test and McNeamr test methods
were used respectively according to the type of data to
analyze whether there were significant differences or
relevance between the various indicators. P < 0.05 was
considered statistically significant.Results
Claudin-6 expression in ovarian cancer tissues and its
clinical significance
Immunohistochenical staining results revealed that
claudin-6 protein was localized in both the cell membrane
and cytoplasm. Expression of claudin-6 was 69.4℅ (25/36)
in the ovarian carcinomas and 34.6℅ (9/26) in the ovarian
serous adenomas and expression of claudin-6 in ovarian
papillary serous carcinomas significantly was significantly
higher than that in ovarian serous adenomas (Table 1,
Figure 1A and 1B, chi-square test χ2 = 7.3946, P = 0.0065).
As shown in Table 1, the expression of claudin-6 was not
associated with pathological grade (P = 0.6964), clinical
stage (P = 0.7771), metastasis (P = 0.2674) or patient age
(P = 0. 6964) in this study.
Table 1 Expression of claudin-6, occludin and MMP-2and clinicopathological characteristics in breast
carcinoma patients
Variables No. Claudin-6 Occludin MMP-2
Positive Negative p Positive Negative p Positive Negative p
Patient Age
20-40 9 6 3 0.696* 4 5 0.846* 6 3 0.900*
41-60 20 14 6 11 9 15 5
61-80 7 5 2 4 3 5 2
Histology
Ovarian papillary serous carcinoma 36 25 11 0.007 19 17 0.108* 26 10 0.001
Ovarian serous adenomas 26 9 17 19 7 8 18
Pathological Grade
I 14 9 5 0.696* 8 6 0.918* 9 5 0.6820*
II 12 8 4 6 6 9 3
III 10 8 2 5 5 8 2
Clinical Stage
I-II 20 13 7 0.777* 10 10 0.709* 11 9 0.028
III-IV 16 12 4 9 7 15 1
Metastasis
Positive 13 11 2 0.267* 7 6 0.923* 12 1 0.037
Negative 23 14 9 12 11 14 9
chi-square test.
*No statistical significance.
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Immunohistochemical staining indicated that occludin
was located in the membrane or cytoplasm (Figure 1C
and 1D). The expression of occludin was found in 52.
8% (19/36) of ovarian papillary serous carcinomas and
73.1% (19/26) of ovarian serous adenomas. This differ-
ence was not significant (chi-square test χ2 = 2.6220,P =
0.1082), as shown in Table 1. The expression of occludin
was not correlated with pathological grade (P = 0.9184),
clinical stage (P = 0.7090), metastasis (P = 0.9231) or
patient age (P = 0. 8460) (Table 1).MMP-2 expression
By immunohistochemistry, MMP-2 expression was lo-
cated in the membrane or cytoplasm, (Figure 1E, 1F). The
expression of MMP-2 was positive in 72.2℅ (26/36) of
ovarian papillary serous carcinomas and 30.8℅ (8/26) of
ovarian serous adenomas (Table 1). The MMP-2 Protein
in ovarian papillary serous carcinomas was significantly
elevated relative to ovarian serous adenomas. (chi-square
test χ2 = 10.4747, P = 0.0012 < 0.05). The expression of
MMP-2 was positively correlated with clinical stage
(P = 0.0275) (Table 1, Figure 2A and 2B) and metastasis
(P = 0.0367) (Table 1). The expression of MMP-2 was
not correlated with pathological grade (P = 0.6820) or
patient age (P = 0. 8996) (Table 1).Correlation of claudin-6, occludin and MMP-2 expression
in ovarian carcinoma
Correlation between the expression of claudin-6, occludin
and MMP-2 was evaluated in ovarian carcinoma specimens
by McNemar test. The expression of claudin-6 was not cor-
related with that of occludin (McNemar test χ2 = 2.5714,
P = 0.1088> 0.05) or MMP-2 (McNemar test χ2 = 1.0000,
P = 0.3173> 0.05) (Table 2). Similarly, the expression of
occludin was not correlated with MMP-2 ( McNemar test
χ2 = 2.0000,P = 0.1573) (Table 3).Discussion
TJs located in the junctional complex of epithelial cells and
endothelial cells, consist of three essential membrane pro-
teins: claudins, occludins and JAM. These maintain cell
polarity, adhesion, and regulate cell proliferation and differ-
entiation [16]. Recent studies suggest that the invasive and
metastatic characteristics of ovarian cancer may be associ-
ated with abnormal structure and function of TJs in
addition to activation of matrix metalloproteinases [5]. Cur-
rently the possibility that abnormalities in TJ s protein ex-
pression relate to the invasion and metastasis of ovarian
cancer has not been widely examined. Similarly, studies
concerning the correlation of claudin-6, occludin and
MMP-2 with ovarian cancer have rarely been reported.





Figure 1 The immunohistochemical expression of claudin-6, occludin and MMP-2 in ovarian papillary serous carcinoma and ovarian
serous adenoma. A, Claudin-6 was strongly expressed in ovarian carcinoma; B, Claudin-6 was weakly expressed in ovarian serous adenoma; C,
Occludin expression in ovarian carcinoma; D, Occludin expression in ovarian serous adenoma; E, MMP-2 was strongly expressed in ovarian
carcinoma; F, MMP-2 was weakly expressed in ovarian serous adenoma. [bar line = 50 μm].
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cases of ovarian papillary serous carcinomas and 26
patients with ovarian serous adenomas. We looked for
correlations between the expression of these parame-
ters and clinical stage, histological grade and metasta-
sis. Our data show that the positive expression rates of
claudin-6 and MMP-2 were higher in ovarian papillaryA
Figure 2 The expression of MMP-2 in clinical stage I and clinical stage
stage I ovarian carcinoma; B, MMP-2 was strongly expressed in clinical stagserous carcinoma than in ovarian serous adenomas
specimens. Also, MMP-2 expression was enhanced with
increased clinical stage, and metastasis. We speculate that
the up-regulation of claudin-6 plays a role in ovarian
cancer carcinogenesis and metastasis by influencing
structure and function of TJs or promoting the activa-
tion of MMP-2 that degrades the extracellular matrix,B
III ovarian carcinoma. A, MMP-2 was weakly expressed in Clinical
e III ovarian carcinoma. [bar line = 50 μm].
Table 2 Correlation between the expression of MMP-2, occludin and claudin-6
Item Occludin (+) Occludin (−) P MMP-2(+) MMP-2(−) P
Claudin-6(+) 14 10 0.109* 17 10 0.317*
Claudin-6(−) 4 8 6 3
McNemar test.
*No statistical significance.
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ment of ovarian cancer carcinogenesis and metastasis.Expression of Claudin-6 in ovarian cancer tissue and
its significance
The loss of cell polarity and abnormal permeability is a char-
acteristic change in malignant epithelial tumors [17,18]. TJs
are the key structures that maintain these functions in epi-
thelial cells, but structure and function of TJs are changed
in many epithelial tumors. Claudins aberrant regulation
was related to abnormal structure and function of TJs [9].
It has been reported that several kinds of tumors have re-
lation with up-regulation of claudins. For example,
claudin-3 and claudin-4 were expressed at high levels in
endometrioid adenocarcinoma [19] and prostate cancer
[20]; claudin-10 expression was up-regulated in hepatocel-
lular carcinoma [21] and thyroid papilloma [22]; claudin-2
has been reported to be up-regulated in thyroid cancer
and endometrial cancer [23]. Claudins have also been
shown to promote tumor invasion by the activation of
MMPs [5,11,12]. Similarly, down-regulation of several
claudin proteins has also been reported to promote tumor
invasion by the reduction of TJs function in various can-
cers. For example, down-regulation of claudin-1 has been
found in colon cancer [24]. Down-regulation of claudin-7
has been found in invasive breast cancer [25]. These re-
ports of down-regulated TJs expression in cancer are con-
sistent with the generally accepted idea that tumorigenesis
is accompanied by a disruption of TJs, a process that may
play a critical role in the loss of cohesion and invasiveness
observed in cancer cells. Claudin-6 belongs to the family
of claudin proteins. We found previously that, claudin-6
was down-regulated in breast cancer cells [26,27] as well
as in gastric cancer [28], but up-regulated in ovarian can-
cer cells. We recently found claudin-6 inhibited invasion
in breast cancer cells by reversing EMT (data not show).
Together, the up-regulation and down-regulation of theTable 3 Correlation between the expression of MMP-2
and occludin
Item Occludin (+) Occludin (−) P
MMP-2(+) 10 6 0.157*
MMP-2(−) 12 8
McNemar test.
*No statistical significance.claudin proteins are both related to various human cancers
due to high tissue-specific expression manners of claudin
proteins. We speculated that aberrant expression of
claudin-6 protein may play a key role in the invasion and
metastasis of ovarian cancer and other cancers.
Our data show that the expression of claudin-6 in 36
ovarian papillary serous carcinomas is significantly higher
than in 26 ovarian serous adenomas; claudin-6 expression
in metastatic tumors was significantly higher than in the
tumors without metastasis. Though this difference was
not statistically significant, it suggests that up-regulation
of caudin-6 may play a role in the occurrence, invasion
and metastasis of ovarian cancer. It is unclear why there is
elevated expression of claudins and associated destruction
of TJs in tumorigenesis and metastasis. However, it seems
possible that the aberrant up-regulation of claudins may
alter the constituent ratio of TJs. On the one hand, it
may cause changes in the structure of TJs leading to loss
of the integrity of TJ function, increases in cell gap and
loss of robustness of the cell junction. On the other
hand, it may lead to disappearance of cell polarity,
weakening of intercellular adhesion and facilitation of
invasion. These changes may regulate tumor cell prolif-
eration, differentiation, survival and apoptosis though
some signal transduction pathways, which play a role in
occurrence, invasion and metastasis of tumor. In
addition, up-regulation of claudins may activate MMPs
that also promote invasion and metastasis of tumors.
We speculate that up-regulation of claudin-6 may have
the same mechanism play a role in occurrence, invasion
and metastasis of ovarian cancer.Occludin expression in ovarian cancer tissue and
its significance
Occludin is a transmembrane protein that has an im-
portant role in maintaining function of TJs [29]. Our re-
sults show that occludin expression in is low in
comparison with its expression in ovarian serous aden-
omas, occludin expression is less in poorly differentiated
ovarian carcinoma than in well-differentiated tumors.
Although this result was not statistically significant, it
suggests that occludin expression in ovarian cancer may
play a role in the occurrence and development of ovar-
ian tumors. Currently relevant information found occlu-
din expression to be low in a variety of tumors, such as
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tissue [30-32]. Osanai et al. [33] transfected the occludin
gene into tumor cells and found that it can affect the
phenotype of the tumor cells, in particular by increasing
the sensitivity of transfected tumor cells to apoptotic fac-
tors, thereby acting as a tumor suppressor. It has been
suggested that inhibition of occludin may act on TJs dir-
ectly or indirectly to bind with factors that regulate cell
proliferation, differentiation and cell cycle, receiving and
imparting PKC and Rho protein etc. molecular signaling,
regulating tumor cell survival [34].
MMP-2 expression in ovarian cancer tissue and
its significance
Campo et al. [35] found MMP-2 was undetectable or
expressed at low levels in benign ovarian tumors and
low-grade malignant tumors without invasion. Such tu-
mors had a continuous basement membrane. In contrast,
MMP-2 expression was high and basement membranes
were widely missing in aggressive tumors accompanied by
distant organ and lymph node metastasis. MMP-2 and
MMP-9 have been related to poor prognosis and lung
metastasis in breast cancer [36,37]. Subsequently Autio-
Harnainen [38] found expression of MMP-2 in both
epithelial and stromal cells by immunohistochemistry in
their studies of ovarian tumors. Our studies showed that
MMP-2 expression was higher in ovarian papillary ser-
ous carcinomas than in ovarian serous adenomas. MMP-2
expression in ovarian cancer was higher as the clinical
stage increased and MMP-2 positive expression was sig-
nificantly higher (P < 0.05) in ovarian cancers with metas-
tasis than without metastasis. This result suggests that
high expression of MMP-2 may be related to the invasion
and metastasis of ovarian cancer and supports the view of
Parsons [39], that high expression of MMP-2 in ovarian
cancer suggests that invasion and metastasis has occurred.
Correlation of expression of claudin-6, occluding
and MMP-2
Our correlation studies showed that expression of the TJ
proteins claudin-6, occludin and MMP-2 were not corre-
lated in ovarian cancer. The experimental results show
that the expression of MMP-2 was up-regulated in ovar-
ian cancer. Claudin-6 was also increased. To some ex-
tent, the high expression of MMP-2 may be due to
increased Claudin-6 expression, thus speeding up the
extracellular matrix degradation and resulting in the
damage to the structure of TJs. Agarwal et al. [5] found
that up-regulation of claudin-3 and claudin-4 in ovarian
cancer promoted metastasis of ovarian cancer. These
workers thought that the up-regulation of claudin-3 and
claudin-4 may take effect by increasing MMP-2. MMP-2
not only regulates the adhesion between cells thereby af-
fecting invasive metastasis of tumor cell, but also induceactivation of extracellular protein, and plays a key role in
attracting inflammatory cells and spontaneously stimulating
migration of tumor cells [40]. MMP-2 can also promote
tumor angiogenesis by rebuilding the extracellular matrix
[41]. MMP2 is a prognostic indicator in patients with
lymph node-negative breast carcinomas [42]. Many genes
can be significant prognostic and diagnostic markers for
ovarian tumors. For example, estrogen maybe a diagnostic
marker in some kinds of tumor [43], Eag is a prognostic
indicator in ovarian cancer [44], p53 and metallothionein
may be helpful in the typing of borderline and malignant
ovarian tumors [45]. The difference in expression of P53,
MAPK, topoisomerase II alpha and Ki67 between low and
high-grade group indicate these genes may be the prog-
nostic markers in ovarian cancer [46]. To determine
whether MMP2 is a prognostic indicator in ovarian tu-
mors need further researches in the future.
Our present study shows that claudin-6 and MMP-2
were both up-regulated in ovarian cancer, MMP-2 ex-
pression was enhanced with increased clinical stage and
metastasis indicates that claudin-6 and MMP-2 may
play an important role in the progression of ovarian
cancer. However, the correlations between claudin-6 ex-
pression with occludin and MMP-2 expression have not
been observed.
Conclusion
In summary, the up-regulation of claudin-6 may result
in abnormal structure and function of TJs and activation
of MMP-2 both of which can result in some of the
highly invasive tumor cells acquiring invasive and meta-
static phenotype. Claudin-6 and MMP-2 can be used as
important indicators for the judgment of malignant be-
havior of ovarian cancer such as invasion and metastasis.
However, the exact mechanism responsible for the oc-
currence, progression and metastasis of ovarian cancer is
not completely understood and needs further studies.
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